<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7520644\results\search\disease\results.xml">
  <result pre="Group Inc pmcid: 7520644jWJBC.v11.i2.pg14 doi: 10.4331/wjbc.v11.i2.14 : Field Of Vision" exact="Immunological" post="aspects of COVID-19: What do we know? VelikovaTsvetelina Veselinova[],"/>
  <result pre="was selected by an in-house editor and fully peer-reviewed by" exact="external" post="reviewers. It is distributed in accordance with the Creative"/>
  <result pre="the use is non-commercial. Abstract The newly emerged coronavirus (severe" exact="acute" post="respiratory syndrome coronavirus 2 SARS-CoV-2) and the disease that"/>
  <result pre="use is non-commercial. Abstract The newly emerged coronavirus (severe acute" exact="respiratory" post="syndrome coronavirus 2 SARS-CoV-2) and the disease that it"/>
  <result pre="is non-commercial. Abstract The newly emerged coronavirus (severe acute respiratory" exact="syndrome" post="coronavirus 2 SARS-CoV-2) and the disease that it causes"/>
  <result pre="coronavirus (severe acute respiratory syndrome coronavirus 2 SARS-CoV-2) and the" exact="disease" post="that it causes coronavirus disease 2019 (COVID-19) have changed"/>
  <result pre="coronavirus 2 SARS-CoV-2) and the disease that it causes coronavirus" exact="disease" post="2019 (COVID-19) have changed the world we know. Yet,"/>
  <result pre="the disease, where the principal and effective immune response towards" exact="viral infection" post="is the cell-mediated immunity. The clinical picture of COVID-19,"/>
  <result pre="disease, where the principal and effective immune response towards viral" exact="infection" post="is the cell-mediated immunity. The clinical picture of COVID-19,"/>
  <result pre="individual's immune system determines the onset and development of the" exact="disease" post="significantly. SARS-CoV-2 COVID-19 Immune memory Anti-SARS-CoV-2 antibodies COVID-19 treatment"/>
  <result pre="antibodies COVID-19 treatment Plasma therapy Core Tip: Since the coronavirus" exact="disease" post="2019 (COVID-19) results from the interaction between the severe"/>
  <result pre="disease 2019 (COVID-19) results from the interaction between the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) virus and the individualâ€²s"/>
  <result pre="2019 (COVID-19) results from the interaction between the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) virus and the individualâ€²s immune"/>
  <result pre="(COVID-19) results from the interaction between the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) virus and the individualâ€²s immune system,"/>
  <result pre="that its onset and development significantly depend on this communication." exact="Immunological" post="aspects of the disease reflect the importance of the"/>
  <result pre="development significantly depend on this communication. Immunological aspects of the" exact="disease" post="reflect the importance of the immune system to inhibit"/>
  <result pre="reflect the importance of the immune system to inhibit the" exact="viral" post="factors and to control and regulate the pathophysiological processes"/>
  <result pre="virus, the development of new technologies for the detection of" exact="infection" post="and effective vaccines. However, much more information remains unclear"/>
  <result pre="verified knowledge of the SARS-CoV-2 virus and COVID-19. EPIDEMIOLOGY OF" exact="SEVERE" post="ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION The novel coronavirus"/>
  <result pre="knowledge of the SARS-CoV-2 virus and COVID-19. EPIDEMIOLOGY OF SEVERE" exact="ACUTE" post="RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION The novel coronavirus (formerly"/>
  <result pre="in Wuhan, China. Later, it received the name the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) that stands for severe"/>
  <result pre="Wuhan, China. Later, it received the name the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) that stands for severe acute"/>
  <result pre="China. Later, it received the name the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) that stands for severe acute respiratory"/>
  <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that stands for severe" exact="acute" post="respiratory syndrome coronavirus 2. Now it is the cause"/>
  <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2) that stands for severe acute" exact="respiratory" post="syndrome coronavirus 2. Now it is the cause of"/>
  <result pre="syndrome coronavirus 2 (SARS-CoV-2) that stands for severe acute respiratory" exact="syndrome" post="coronavirus 2. Now it is the cause of the"/>
  <result pre="The latter include those from common cold to more severe" exact="respiratory" post="complaints as well as gastroenteric, hepatic, and neurological symptoms[2]."/>
  <result pre="coronavirus members. These are HCoV-OC43, HCoV229E, SARS-CoV, HCoV-HKU1, Middle East" exact="respiratory" post="syndrome corona virus (MERS-CoV), and HCoVNL63[3,4]. Over the last"/>
  <result pre="members. These are HCoV-OC43, HCoV229E, SARS-CoV, HCoV-HKU1, Middle East respiratory" exact="syndrome" post="corona virus (MERS-CoV), and HCoVNL63[3,4]. Over the last twenty"/>
  <result pre="the evolution and host distribution of these SARS-CoV-2-related viruses[8,9]. Coronavirus" exact="disease" post="2019 (COVID-19) is the illness associated with SARS-CoV-2 infection."/>
  <result pre="(COVID-19) is the illness associated with SARS-CoV-2 infection. The clinical" exact="syndrome" post="is characterized by variable symptoms, ranging from mild upper"/>
  <result pre="clinical syndrome is characterized by variable symptoms, ranging from mild" exact="upper" post="respiratory symptoms to severe interstitial pneumonia and acute respiratory"/>
  <result pre="syndrome is characterized by variable symptoms, ranging from mild upper" exact="respiratory" post="symptoms to severe interstitial pneumonia and acute respiratory distress"/>
  <result pre="symptoms, ranging from mild upper respiratory symptoms to severe interstitial" exact="pneumonia" post="and acute respiratory distress syndrome (ARDS)[10,11]. SARS-CoV-2 and SARS-CoV"/>
  <result pre="from mild upper respiratory symptoms to severe interstitial pneumonia and" exact="acute" post="respiratory distress syndrome (ARDS)[10,11]. SARS-CoV-2 and SARS-CoV and MERS-CoV"/>
  <result pre="mild upper respiratory symptoms to severe interstitial pneumonia and acute" exact="respiratory" post="distress syndrome (ARDS)[10,11]. SARS-CoV-2 and SARS-CoV and MERS-CoV belong"/>
  <result pre="respiratory symptoms to severe interstitial pneumonia and acute respiratory distress" exact="syndrome" post="(ARDS)[10,11]. SARS-CoV-2 and SARS-CoV and MERS-CoV belong to the"/>
  <result pre="evidence to suggest airborne transmission, as very minimal to no" exact="viral" post="RNA was detected in airborne samples, and no viral"/>
  <result pre="no viral RNA was detected in airborne samples, and no" exact="viral" post="RNA was found in urine or serum samples of"/>
  <result pre="features are probably due to other factors, such as high" exact="viral" post="concentrations in the upper airways and the potential asymptomatic"/>
  <result pre="to other factors, such as high viral concentrations in the" exact="upper" post="airways and the potential asymptomatic spread of SARS-CoV-2[18,19]. Also,"/>
  <result pre="transmission of SARS-CoV-2 is likely since the virus can remain" exact="infectious" post="depending on the inoculum shed. It was shown that"/>
  <result pre="that the COVID-19 virus is primarily transferred between people through" exact="respiratory" post="droplets and contact routes[21]. Transmission due to droplets is"/>
  <result pre="documented in close contact (considered within 1-1.5 m) with a" exact="symptomatic" post="person (e.g., coughing or sneezing). The risk is estimated"/>
  <result pre="of mucosae (mouth and nose) or conjunctiva (eyes) to potentially" exact="infective" post="respiratory droplets. Fomites in the immediate environment around the"/>
  <result pre="mucosae (mouth and nose) or conjunctiva (eyes) to potentially infective" exact="respiratory" post="droplets. Fomites in the immediate environment around the infected"/>
  <result pre="is one of the significant pathogens that targets the human" exact="respiratory" post="system primarily[10]. SARS-CoV-2 was found to have higher rates"/>
  <result pre="(2-14 d)[24]. However, the case fatality rate (CFR) of any" exact="disease" post="is not fixed and varies with location and time."/>
  <result pre="COVID-19 or as a result of an exacerbation of a" exact="chronic" post="disease/or another sudden acute medical condition, such as stroke"/>
  <result pre="result of an exacerbation of a chronic disease/or another sudden" exact="acute" post="medical condition, such as stroke and heart failure, but"/>
  <result pre="a chronic disease/or another sudden acute medical condition, such as" exact="stroke" post="and heart failure, but with a positive polymerase chain"/>
  <result pre="chronic disease/or another sudden acute medical condition, such as stroke" exact="and heart" post="failure, but with a positive polymerase chain reaction for"/>
  <result pre="disease/or another sudden acute medical condition, such as stroke and" exact="heart" post="failure, but with a positive polymerase chain reaction for"/>
  <result pre="the human body, it spread around the world in a" exact="short" post="time. The air-drop mechanism is straightforward to implement. The"/>
  <result pre="COVID-19. From an epidemiological point of view, mild and asymptomatic" exact="infections" post="are hazardous because people have no idea that they"/>
  <result pre="AND PATHOLOGICAL EFFECTS As already mentioned above, COVID-19 is an" exact="infection" post="that has shortly become a health problem of global"/>
  <result pre="of SARS-CoV and MERS-CoV, respectively[28]. Mutations and recombination of the" exact="viral" post="genome frequently occur due to error-prone RNA-dependent-RNA polymerases of"/>
  <result pre="polymerases of the CoV. These events are closely related to" exact="viral" post="adaptation[27]. CoV proteins include structural proteins: Spike (S), envelope"/>
  <result pre="with unknown function. S protein is a glycoprotein essential for" exact="viral" post="entry by attachment and fusion to the cellular membrane"/>
  <result pre="(Figure 1). It is the main presented antigen on the" exact="viral" post="surface and a target of neutralizing antibodies formed during"/>
  <result pre="virus[28]. Figure 1 Virulence factors and immune mechanisms during severe" exact="acute" post="respiratory syndrome coronavirus 2 infection. After the recognition of"/>
  <result pre="Figure 1 Virulence factors and immune mechanisms during severe acute" exact="respiratory" post="syndrome coronavirus 2 infection. After the recognition of the"/>
  <result pre="1 Virulence factors and immune mechanisms during severe acute respiratory" exact="syndrome" post="coronavirus 2 infection. After the recognition of the virus"/>
  <result pre="the virus by angiotensin-converting enzyme 2 and/or TMPRSS2 receptors, severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) internalizes in the host"/>
  <result pre="virus by angiotensin-converting enzyme 2 and/or TMPRSS2 receptors, severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) internalizes in the host cell."/>
  <result pre="by angiotensin-converting enzyme 2 and/or TMPRSS2 receptors, severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) internalizes in the host cell. Via"/>
  <result pre="coronavirus 2 (SARS-CoV-2) internalizes in the host cell. Via several" exact="secondary" post="messengers, the respiratory mucosal cell is stimulated to secrete"/>
  <result pre="internalizes in the host cell. Via several secondary messengers, the" exact="respiratory" post="mucosal cell is stimulated to secrete cytokines and present"/>
  <result pre="respiratory mucosal cell is stimulated to secrete cytokines and present" exact="viral" post="antigens via major histocompatibility complex (human leukocyte antigen) class"/>
  <result pre="cytotoxic cells as a part of cellular immunity against every" exact="viral infection." post="Antigen-presenting cells, such as macrophages and dendritic cells, can"/>
  <result pre="Antigen-presenting cells, such as macrophages and dendritic cells, can present" exact="viral" post="particles via human leukocyte antigen class II molecules and"/>
  <result pre="a vast majority of cytokines, leading to cytokines storms and" exact="acute" post="respiratory distress syndrome. Th cells stimulate B cells to"/>
  <result pre="vast majority of cytokines, leading to cytokines storms and acute" exact="respiratory" post="distress syndrome. Th cells stimulate B cells to produce"/>
  <result pre="SARS-CoV-2 antigens, part of the humoral immunity against the virus." exact="Viral" post="replication and shedding are not shown. ARDS: Acute respiratory"/>
  <result pre="the virus. Viral replication and shedding are not shown. ARDS:" exact="Acute respiratory distress syndrome;" post="SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; ACE2: Angiotensin-converting"/>
  <result pre="virus. Viral replication and shedding are not shown. ARDS: Acute" exact="respiratory" post="distress syndrome; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2;"/>
  <result pre="shedding are not shown. ARDS: Acute respiratory distress syndrome; SARS-CoV-2:" exact="Severe" post="acute respiratory syndrome coronavirus 2; ACE2: Angiotensin-converting enzyme 2."/>
  <result pre="are not shown. ARDS: Acute respiratory distress syndrome; SARS-CoV-2: Severe" exact="acute" post="respiratory syndrome coronavirus 2; ACE2: Angiotensin-converting enzyme 2. SARS-CoV"/>
  <result pre="not shown. ARDS: Acute respiratory distress syndrome; SARS-CoV-2: Severe acute" exact="respiratory" post="syndrome coronavirus 2; ACE2: Angiotensin-converting enzyme 2. SARS-CoV and"/>
  <result pre="shown. ARDS: Acute respiratory distress syndrome; SARS-CoV-2: Severe acute respiratory" exact="syndrome" post="coronavirus 2; ACE2: Angiotensin-converting enzyme 2. SARS-CoV and SARS-CoV-2"/>
  <result pre="required for MERS-CoV entry. After the virus enters the cell," exact="viral" post="RNA is released and involved in consecutive processes of"/>
  <result pre="RNA is released and involved in consecutive processes of new" exact="viral" post="particle formation, which are then released[29]. ACE-2 receptors are"/>
  <result pre="are then released[29]. ACE-2 receptors are mainly expressed in the" exact="vascular" post="epithelium, renal tubular epithelium, and Leydig cells in the"/>
  <result pre="released[29]. ACE-2 receptors are mainly expressed in the vascular epithelium," exact="renal tubular" post="epithelium, and Leydig cells in the testes. For this"/>
  <result pre="in the testes. For this reason, SARS-CoV might lead to" exact="hypogonadism" post="and harm male fertility. In the respiratory system, SARS-CoV-2"/>
  <result pre="might lead to hypogonadism and harm male fertility. In the" exact="respiratory" post="system, SARS-CoV-2 enters the alveoli by binding to the"/>
  <result pre="by binding to the ACE-2 receptors, predominantly expanded on the" exact="type II" post="pneumocytes[30]. Once infected, type II pneumocytes are destroyed, and"/>
  <result pre="receptors, predominantly expanded on the type II pneumocytes[30]. Once infected," exact="type II" post="pneumocytes are destroyed, and surfactant production is reduced. Macrophages"/>
  <result pre="tissue of the lungs. Macrophages secrete interleukin (IL)-1, IL-6, and" exact="tumor" post="necrosis factor alpha (TNFÎ±), which cause vasodilatation and high"/>
  <result pre="and lymphocytes migration to the affected area. Alveoli edema causes" exact="respiratory" post="failure due to blood-gas exchange disturbance. Nonstructural proteins might"/>
  <result pre="of the host and play a crucial role in the" exact="viral" post="virulence and pathophysiology of SARS-CoV-2 infection[30]. In vitro and"/>
  <result pre="SARS-CoV-2 infection[30]. In vitro and ex vivo examinations compared the" exact="viral" post="tropism of SARS-CoV-2 with that of SARS-CoV, MERS-CoV, and"/>
  <result pre="MERS-CoV, and 2009 pandemic influenza H1N1. It showed more extensive" exact="infection" post="of bronchial epithelium, ciliated cells, and goblet cells with"/>
  <result pre="comparison with the lung parenchyma. However, the endothelium of the" exact="blood vessels" post="was not found to be infected[32]. SARS-CoV-2 could also"/>
  <result pre="be detected in tears, anal swabs, and stool specimens. Moreover," exact="infection" post="and productive replication of the virus were observed in"/>
  <result pre="replication of the virus were observed in the conjunctiva and" exact="colorectal carcinoma" post="cell lines. These findings suggest that conjunctiva and the"/>
  <result pre="of the virus were observed in the conjunctiva and colorectal" exact="carcinoma" post="cell lines. These findings suggest that conjunctiva and the"/>
  <result pre="conjunctiva and the bronchus epithelium might also be portals of" exact="infection" post="and also poses the possibility of fecal-oral transmission. Various"/>
  <result pre="also poses the possibility of fecal-oral transmission. Various routes of" exact="viral" post="transmission would explain the extensive spread of the SARS-CoV-2"/>
  <result pre="RNA[33]. Moreover, studies in mice showed that SARS-CoV and MERS-CoV" exact="infection" post="might inhibit the most potent anti-viral molecules, such as"/>
  <result pre="described mechanisms behind this inhibition in MERS-CoV include blocking of" exact="melanoma" post="differentiation-associated protein 5, inhibiting the nuclear transport of IFN"/>
  <result pre="system is a critical factor in the treatment of current" exact="infection" post="and the development of specific drugs. HUMORAL AND CELLULAR"/>
  <result pre="exerted by virus-specific B and T lymphocytes, respectively. Like common" exact="acute" post="viral infections, the antibody production against SARS-CoV viruses has"/>
  <result pre="by virus-specific B and T lymphocytes, respectively. Like common acute" exact="viral" post="infections, the antibody production against SARS-CoV viruses has a"/>
  <result pre="protective[29]. SARS-specific IgG antibodies are predominantly against S- and N-proteins." exact="Immunological" post="follow-up revealed a progressive increase in plasma SARS-CoV-2-specific IgM"/>
  <result pre="care units and the need for supportive mechanical ventilation. This" exact="secondary" post="deterioration is reminiscent of SARS-CoV, in which 80% of"/>
  <result pre="of SARS-CoV, in which 80% of patients with SARS-CoV develop" exact="acute" post="respiratory disease at the time of anti-viral IgG seroconversion[37]."/>
  <result pre="SARS-CoV, in which 80% of patients with SARS-CoV develop acute" exact="respiratory" post="disease at the time of anti-viral IgG seroconversion[37]. IgG"/>
  <result pre="in which 80% of patients with SARS-CoV develop acute respiratory" exact="disease" post="at the time of anti-viral IgG seroconversion[37]. IgG seroconversion"/>
  <result pre="patients who produce anti-S-neutralizing antibodies at the onset of the" exact="disease" post="have a higher risk of death. The mechanisms behind"/>
  <result pre="a role. In addition, a phenomenon called antibody-mediated enhancement of" exact="viral infection" post="may be responsible for persistent viral load and subsequently"/>
  <result pre="role. In addition, a phenomenon called antibody-mediated enhancement of viral" exact="infection" post="may be responsible for persistent viral load and subsequently"/>
  <result pre="antibody-mediated enhancement of viral infection may be responsible for persistent" exact="viral" post="load and subsequently cause a direct or indirect effect"/>
  <result pre="into account that the principal and effective immune response towards" exact="viral infection" post="is cell-mediated immunity. A clinical case of mild SARS-2-CoV"/>
  <result pre="account that the principal and effective immune response towards viral" exact="infection" post="is cell-mediated immunity. A clinical case of mild SARS-2-CoV"/>
  <result pre="infection is cell-mediated immunity. A clinical case of mild SARS-2-CoV" exact="infection" post="and favorable outcome for the patient revealed that the"/>
  <result pre="and CD4+CXCR5+ICOS+PD-1+ Th follicular cells, appear in the blood during" exact="viral" post="clearance (day 7; 1.48%) and peak on day 8"/>
  <result pre="critical players in the cell-mediated immune response that accompanies any" exact="viral infection." post="Helper CD4+ T cells simultaneously expressing CD38 and HLA-DR"/>
  <result pre="compared to healthy donors (0,63% Â± 0.28%), although being in" exact="lower" post="percentages than for CD8+ T cells. CD38+HLA-DR+CD8+ T cells"/>
  <result pre="which are associated with the immunopathology of COVID-19, showed a" exact="lower" post="frequency of these cells in the blood of this"/>
  <result pre="No differences were found in activated HLA-DR+CD3-CD56+ NK cells during" exact="infection" post="and compared to healthy levels[37]. However, recent data conclude"/>
  <result pre="recovered patients for up to 4 years, even in the" exact="absence of" post="viral antigens[39]. Moreover, other studies detected SARS-CoV-S protein-specific memory"/>
  <result pre="for up to 4 years, even in the absence of" exact="viral" post="antigens[39]. Moreover, other studies detected SARS-CoV-S protein-specific memory T"/>
  <result pre="and MERS-CoV-specific CD8+ T cells in mice, mainly involved in" exact="viral" post="clearance[41]. These findings are a reasonable basis for designing"/>
  <result pre="of human Th17 cell differentiation, are also involved in stimulating" exact="vascular" post="permeability and leakage. Nevertheless, it was shown that patients"/>
  <result pre="the hypothesis that enhanced IL-17-related pathways, including higher IL-17 but" exact="lower" post="IFNÎ³ and IFNÎ±, are associated with worse outcomes for"/>
  <result pre="cells to the cytokine storm, Th17 cells may likely promote" exact="pulmonary" post="edema, tissue damage, and lung failure. In line with"/>
  <result pre="Some of the immunological responses that are accompanying the SARS-CoV-2" exact="infection" post="are presented in Figure 1. CLINICAL MANIFESTATIONS OF COVIDâ€&quot;19"/>
  <result pre="are presented in Figure 1. CLINICAL MANIFESTATIONS OF COVIDâ€&quot;19 A" exact="symptomatic" post="COVID-19 case is defined as an infected person with"/>
  <result pre="signs or symptoms of COVID-19[46]. The incubation period of the" exact="disease" post="is 5-6 d on average but can be up"/>
  <result pre="to 14 d. Critical epidemiological and immunological aspects of the" exact="disease" post="are that an infected person may be contagious 1-3"/>
  <result pre="mild clinical course, and another 40% present with moderate disease." exact="Severe" post="disease that requires oxygen support is observed in about"/>
  <result pre="clinical course, and another 40% present with moderate disease. Severe" exact="disease" post="that requires oxygen support is observed in about 15%"/>
  <result pre="patients. Five percent of the infected ones develop a severe" exact="disease" post="that progresses to respiratory failure (ARDS) but also sepsis"/>
  <result pre="the infected ones develop a severe disease that progresses to" exact="respiratory" post="failure (ARDS) but also sepsis and septic shock, thromboembolism,"/>
  <result pre="that progresses to respiratory failure (ARDS) but also sepsis and" exact="septic shock," post="thromboembolism, multiorgan failure, including acute kidney, and cardiac injury[48]."/>
  <result pre="but also sepsis and septic shock, thromboembolism, multiorgan failure, including" exact="acute" post="kidney, and cardiac injury[48]. Advanced age, smoking, as well"/>
  <result pre="shock, thromboembolism, multiorgan failure, including acute kidney, and cardiac injury[48]." exact="Advanced" post="age, smoking, as well as comorbidities such as diabetes,"/>
  <result pre="as well as comorbidities such as diabetes, hypertension, cardiac and" exact="chronic" post="lung disease, cerebrovascular diseases, immunosuppression, and cancer have been"/>
  <result pre="well as comorbidities such as diabetes, hypertension, cardiac and chronic" exact="lung disease," post="cerebrovascular diseases, immunosuppression, and cancer have been reported to"/>
  <result pre="hypertension, cardiac and chronic lung disease, cerebrovascular diseases, immunosuppression, and" exact="cancer" post="have been reported to predispose to a severe course"/>
  <result pre="severe course of COVID-19. Children and infants usually experience mild" exact="disease" post="or asymptomatic infection[49]. There are no specific clinical symptoms"/>
  <result pre="include sore throat, nasal congestion, headache, nausea, as well as" exact="diarrhea" post="and vomiting. Loss of smell and taste have also"/>
  <result pre="and taste have also been reported. In older people, some" exact="atypical" post="symptoms such as reduced alertness and/or mobility and delirium"/>
  <result pre="some atypical symptoms such as reduced alertness and/or mobility and" exact="delirium" post="might be seen[50,51]. COVID-19 may also present with neurological"/>
  <result pre="COVID-19 may also present with neurological and mental manifestations, including" exact="delirium" post="or encephalopathy, agitation, stroke, meningoencephalitis, anxiety, depression, and sleep"/>
  <result pre="cases, some of these neurological manifestations have been documented without" exact="respiratory" post="symptoms[52,53]. A retrospective study of SARS-CoV-2 infected patients showed"/>
  <result pre="symptoms[52,53]. A retrospective study of SARS-CoV-2 infected patients showed mild" exact="leucopenia" post="in mild cases. Mild to moderate leukocytosis was observed"/>
  <result pre="and D-dimer. These laboratory changes are a result of an" exact="acute" post="and severe inflammatory response[50]. Research on cellular immunity in"/>
  <result pre="crucial factor for the clinical course of COVID-19 and the" exact="disease" post="severity. A common complication of SARS-CoV-2 infection is the"/>
  <result pre="COVID-19 and the disease severity. A common complication of SARS-CoV-2" exact="infection" post="is the development of ARDS. The latter is assumed"/>
  <result pre="cytokine storm - an immunopa-thological event that leads to an" exact="uncontrolled" post="systemic inflammatory response from the release of pro-inflammatory cytokines"/>
  <result pre="storm - an immunopa-thological event that leads to an uncontrolled" exact="systemic" post="inflammatory response from the release of pro-inflammatory cytokines IFNÎ±,"/>
  <result pre="active substances seriously damage the lung parenchyma and lead to" exact="respiratory" post="failure. This severe acute hypoxic status is accompanied by"/>
  <result pre="the lung parenchyma and lead to respiratory failure. This severe" exact="acute" post="hypoxic status is accompanied by increased pulmonary capillary permeability"/>
  <result pre="failure. This severe acute hypoxic status is accompanied by increased" exact="pulmonary" post="capillary permeability and alveolar epithelial cell damage[51]. TNFÎ± and"/>
  <result pre="status is accompanied by increased pulmonary capillary permeability and alveolar" exact="epithelial" post="cell damage[51]. TNFÎ± and IL-6 production in COVID-19 follows"/>
  <result pre="in COVID-19 follows a different pattern than the pattern in" exact="bacterial" post="sepsis or influenza. Furthermore, it was shown that blocking"/>
  <result pre="pathways, IL-6 or IL-1b-driven immune hyperactivation, leading to macrophages activations" exact="syndrome" post="(MAS) or immune dysregulation (Figure 2). Figure 2 The"/>
  <result pre="by a decrease in many cell types, both leading to" exact="acute" post="respiratory distress syndrome. CRP: C-reactive protein; HLA: Human leukocyte"/>
  <result pre="a decrease in many cell types, both leading to acute" exact="respiratory" post="distress syndrome. CRP: C-reactive protein; HLA: Human leukocyte antigen;"/>
  <result pre="leukocyte antigen; Ig: Immunoglobulin; IL: Interleukin; Th: T helper; TNFÎ±:" exact="Tumor" post="necrosis factor alpha. The initiation of pneumonia in COVID-19"/>
  <result pre="T helper; TNFÎ±: Tumor necrosis factor alpha. The initiation of" exact="pneumonia" post="in COVID-19 includes intense antigen presentation, accompanied by elevated"/>
  <result pre="and liver amino-transferases plus infiltrates in the lungs, whereas severe" exact="respiratory" post="failure displays either MAS or deficient HLA-DR expression and"/>
  <result pre="infection[29]. Affecting the whole organism, the cytokine storm is the" exact="primary" post="mechanism that induces disseminated intravascular coagulation (DIC). Pro-inflammatory cytokines"/>
  <result pre="organism, the cytokine storm is the primary mechanism that induces" exact="disseminated intravascular coagulation" post="(DIC). Pro-inflammatory cytokines TNFÎ± and IL-1 suppress the endogenous"/>
  <result pre="event for SARS-CoV-2, SARS-CoV, and MERS-CoV infections. One of the" exact="primary" post="mechanisms for ARDS is the cytokine storm. The latter"/>
  <result pre="for ARDS is the cytokine storm. The latter is a" exact="uncontrolled" post="systemic inflammatory reaction resulting from the release of large"/>
  <result pre="ARDS is the cytokine storm. The latter is a uncontrolled" exact="systemic" post="inflammatory reaction resulting from the release of large amounts"/>
  <result pre="CXCL8, CXCL9, CXCL10, etc.) from immune effector cells during many" exact="viral" post="infection[48,55-57]. Similar to SARS-CoV, individuals with severe MERS-CoV infection"/>
  <result pre="many viral infection[48,55-57]. Similar to SARS-CoV, individuals with severe MERS-CoV" exact="infection" post="show elevated serum levels of IL-6, IFN-Î±, CCL5, CXCL8,"/>
  <result pre="infection[48,55-57]. Similar to SARS-CoV, individuals with severe MERS-CoV infection show" exact="elevated serum" post="levels of IL-6, IFN-Î±, CCL5, CXCL8, and CXCL-10 compared"/>
  <result pre="of coronaviral infections[58]. Another hypothesis on the severity of COVID-19" exact="disease" post="includes the problem associated with the activation of bradykinin"/>
  <result pre="cytokines[59]. Interestingly, without the inactivation of B1 ligands, increased local" exact="vascular" post="permeability is observed in lung mucosa, leading to angioedema."/>
  <result pre="permeability is observed in lung mucosa, leading to angioedema. Probably," exact="angioedema" post="is a typical manifestation of the severe disease onset"/>
  <result pre="angioedema. Probably, angioedema is a typical manifestation of the severe" exact="disease" post="onset and the cause of typical changes visible on"/>
  <result pre="changes visible on the computed tomography scan. The feeling of" exact="choking" post="is observed mainly around day 9, denoted the worsening"/>
  <result pre="9, denoted the worsening of the patients[60]. As any common" exact="viral infection," post="here, we also observed a progressive inflammatory condition with"/>
  <result pre="time, and fibrinogen may remain normal[61]. The pathophysiology of the" exact="disease" post="may be a combination of injury of pulmonary type"/>
  <result pre="of the disease may be a combination of injury of" exact="pulmonary" post="type II pneumocyte, viral pneumonia, ARDS, DIC, sepsis, cytokine"/>
  <result pre="the disease may be a combination of injury of pulmonary" exact="type II" post="pneumocyte, viral pneumonia, ARDS, DIC, sepsis, cytokine storm, MAS,"/>
  <result pre="be a combination of injury of pulmonary type II pneumocyte," exact="viral pneumonia," post="ARDS, DIC, sepsis, cytokine storm, MAS, and overall immune"/>
  <result pre="after infection, unless they experienced ARDS, which led to undetectable" exact="peripheral" post="memory B cell responses[40,65]. It is not yet known"/>
  <result pre="that cellular immunity against the virus is more critical for" exact="viral" post="clearance than the humoral. Thus, the role of Th,"/>
  <result pre="of memory B cells, particularly to coronavirus, hiding in the" exact="secondary" post="lymphoid organs, such as lymph nodes and the spleen"/>
  <result pre="claim that any given person will be protected from the" exact="infection" post="if they reach a specific level of antibodies on"/>
  <result pre="of the unclear immune response and immune memory regarding SARS-CoV-2" exact="infection" post="is the desire of the world to have an"/>
  <result pre="This vaccine is essential to reduce the severity of the" exact="disease" post="and its spread and clear the virus, thus helping"/>
  <result pre="tested in animals. Among them are: Using live attenuated virus," exact="viral" post="vectors, inactivated virus, vaccine subunits, recombinant DNA, and protein"/>
  <result pre="targets to use in the creation of vaccines against SARS-CoV-2" exact="infection" post="and therapy, but additional laboratory and clinical evidence are"/>
  <result pre="evidence are still needed. Some new pharmaceutical drugs, including anti-human" exact="immunodeficiency" post="virus and stem cell drugs, have been shown in"/>
  <result pre="whole family of CoV or against those representatives that cause" exact="disease" post="only in animals. THERAPY OPTIONS RELATED TO THE IMMUNE"/>
  <result pre="in animals. THERAPY OPTIONS RELATED TO THE IMMUNE MECHANISMS COVID-19" exact="infection" post="revealed some treatment options related to the immune responses."/>
  <result pre="the immune responses. If we accept the division of SARS-CoV-2" exact="infection" post="into three stages, at the beginning of the infection"/>
  <result pre="SARS-CoV-2 infection into three stages, at the beginning of the" exact="infection" post="(stage I, an asymptomatic incubation period with or without"/>
  <result pre="as well as the non-severe stage (stage II, a mild" exact="symptomatic" post="period with the presence of a virus in the"/>
  <result pre="to neutralize and eliminate the virus, which will eventually prevent" exact="disease" post="progression to severe stages. The adaptive response, however, occurs"/>
  <result pre="receptors, such as the gut and kidneys. This leads to" exact="lung inflammation," post="mostly mediated by pro-inflammatory immune cells. Inflammation of the"/>
  <result pre="Inflammation of the lungs is the leading cause of life-threatening" exact="respiratory" post="failure in the severe stage of the disease (stage"/>
  <result pre="of life-threatening respiratory failure in the severe stage of the" exact="disease" post="(stage III, severe respiratory symptomatic stage with high viral"/>
  <result pre="in the severe stage of the disease (stage III, severe" exact="respiratory" post="symptomatic stage with high viral load). Therefore, once severe"/>
  <result pre="the severe stage of the disease (stage III, severe respiratory" exact="symptomatic" post="stage with high viral load). Therefore, once severe lung"/>
  <result pre="the disease (stage III, severe respiratory symptomatic stage with high" exact="viral" post="load). Therefore, once severe lung damage occurs, attention should"/>
  <result pre="Treatment modalities related to the immunological mechanisms observed during coronavirus" exact="disease" post="2019. ACE2: Angiotensin-converting enzyme 2; ARDS: Acute respiratory distress"/>
  <result pre="observed during coronavirus disease 2019. ACE2: Angiotensin-converting enzyme 2; ARDS:" exact="Acute respiratory distress syndrome;" post="MHC: Major histocompatibility complex; MSCs: Mesenchymal stromal/stem cells; SARS-CoV-2:"/>
  <result pre="during coronavirus disease 2019. ACE2: Angiotensin-converting enzyme 2; ARDS: Acute" exact="respiratory" post="distress syndrome; MHC: Major histocompatibility complex; MSCs: Mesenchymal stromal/stem"/>
  <result pre="ARDS: Acute respiratory distress syndrome; MHC: Major histocompatibility complex; MSCs:" exact="Mesenchymal" post="stromal/stem cells; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2."/>
  <result pre="syndrome; MHC: Major histocompatibility complex; MSCs: Mesenchymal stromal/stem cells; SARS-CoV-2:" exact="Severe" post="acute respiratory syndrome coronavirus 2. Antibody and plasma therapy"/>
  <result pre="MHC: Major histocompatibility complex; MSCs: Mesenchymal stromal/stem cells; SARS-CoV-2: Severe" exact="acute" post="respiratory syndrome coronavirus 2. Antibody and plasma therapy are"/>
  <result pre="Major histocompatibility complex; MSCs: Mesenchymal stromal/stem cells; SARS-CoV-2: Severe acute" exact="respiratory" post="syndrome coronavirus 2. Antibody and plasma therapy are the"/>
  <result pre="histocompatibility complex; MSCs: Mesenchymal stromal/stem cells; SARS-CoV-2: Severe acute respiratory" exact="syndrome" post="coronavirus 2. Antibody and plasma therapy are the next"/>
  <result pre="Mesenchymal stromal/stem cells; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2." exact="Antibody" post="and plasma therapy are the next therapy option, closely"/>
  <result pre="Preliminary data indicate favorable results for use in patients with" exact="acute" post="and severe SARS-CoV-2 infection. In addition, the development of"/>
  <result pre="antibody therapy is the administration of ready-made antibodies against an" exact="infectious" post="agent to a susceptible individual to prevent or treat"/>
  <result pre="agent to a susceptible individual to prevent or treat an" exact="infectious disease" post="caused by that microorganism. Thus, the passive application of"/>
  <result pre="to a susceptible individual to prevent or treat an infectious" exact="disease" post="caused by that microorganism. Thus, the passive application of"/>
  <result pre="the expected mechanism of action of passive antibody therapy is" exact="viral" post="neutralization and elimination. However, other mechanisms, such as antibody-dependent"/>
  <result pre="serum of recovered individuals can be used prophylactically to prevent" exact="infection" post="in high-risk individuals, such as those with chronic diseases,"/>
  <result pre="to prevent infection in high-risk individuals, such as those with" exact="chronic" post="diseases, medical personnel, and those who have been in"/>
  <result pre="the antibody works by neutralizing the initial inoculum from the" exact="infectious" post="agent, which is probably much less than that in"/>
  <result pre="is probably much less than that in an already developed" exact="infection" post="and a large number of viral copy. In line"/>
  <result pre="in an already developed infection and a large number of" exact="viral" post="copy. In line with this, to be effective, a"/>
  <result pre="serum is administered to patients with clinical manifestations of the" exact="disease" post="to reduce the severity of symptoms and mortality. The"/>
  <result pre="are those associated with the use of blood products -" exact="infectious diseases" post="and allergic reactions to the components of the serum,"/>
  <result pre="and allergic reactions to the components of the serum, including" exact="serum sickness." post="With modern blood banking techniques, these risks are low."/>
  <result pre="used for therapy, there are also theoretical risks for transfusion-related" exact="acute" post="lung injury and antibody-dependent enhancement (ADE) of infection. Several"/>
  <result pre="concerns that antibodies against one type of coronavirus may exacerbate" exact="infection" post="to another virus strain. It is possible to experimentally"/>
  <result pre="to blocking these pro-inflammatory cytokines has been adopted in various" exact="autoimmune diseases." post="We also proposed anti-IL-6 therapy in IBD patients as"/>
  <result pre="blockade is an option but is associated with many more" exact="infectious" post="complications. Also, complement activity has been described and may"/>
  <result pre="of antibodies against cytokines is a general approach in several" exact="autoimmune" post="and autoinflammatory diseases in which one or more cytokines"/>
  <result pre="Anti-inflammatory strategies may provide time, but will not cure the" exact="disease" post="on their own if the virus is present or"/>
  <result pre="on their own if the virus is present or bradykinin-associated" exact="angioedema" post="is not controlled[60]. Although various clinics in China have"/>
  <result pre="and promoting tissue repair, as such MSCs are useful in" exact="acute" post="lung damage caused by lipopolysaccharide[72]. In any case, the"/>
  <result pre="case, the use of MSCs in clinical practice should be" exact="limited" post="to strict indications, taking into account the benefit-risk for"/>
  <result pre="onset and development of COVID-19 significantly depend on this communication." exact="Viral" post="factors, such as viral type, load, titer, in vitro"/>
  <result pre="COVID-19 significantly depend on this communication. Viral factors, such as" exact="viral" post="type, load, titer, in vitro viability, mutations, as well"/>
  <result pre="L-Editor: Filipodia P-Editor: Li JH References 1collab: World Health OrganizationCoronavirus" exact="disease" post="2019 (COVID-19) situation report-48. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200308-sitrep-48-covid-19.pdf?sfvrsnÂ¼16f7ccef_4 2ZhuNZhangDWangWLiXYangBSongJZhaoXHuangBShiWLuRNiuPZhanFMaXWangDXuWWuGGaoGFTanWcollab:"/>
  <result pre="Coronavirus Investigating and Research TeamA Novel Coronavirus from Patients with" exact="Pneumonia" post="in China, 2019N Engl J Med202038272773331978945 3SuSWongGShiWLiuJLaiACKZhouJLiuWBiYGaoGFEpidemiology, Genetic Recombination,"/>
  <result pre="4ChenYLiuQGuoDEmerging coronaviruses: Genome structure, replication, and pathogenesisJ Med Virol20209241842331967327 5PeirisJSGuanYYuenKYSevere" exact="acute" post="respiratory syndromeNat Med200410S88S9715577937 6ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus"/>
  <result pre="coronaviruses: Genome structure, replication, and pathogenesisJ Med Virol20209241842331967327 5PeirisJSGuanYYuenKYSevere acute" exact="respiratory" post="syndromeNat Med200410S88S9715577937 6ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from"/>
  <result pre="6ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med20123671814182023075143 7ZhouPYangXLWangXGHuBZhangLZhangWSiHRZhuYLiBHuangCLChenHDChenJLuoYGuoHJiangRDLiuMQChenYShenXRWangXZhengXSZhaoKChenQJDengFLiuLLYanBZhanFXWangYYXiaoGFShiZLA pneumonia outbreak"/>
  <result pre="man with pneumonia in Saudi ArabiaN Engl J Med20123671814182023075143 7ZhouPYangXLWangXGHuBZhangLZhangWSiHRZhuYLiBHuangCLChenHDChenJLuoYGuoHJiangRDLiuMQChenYShenXRWangXZhengXSZhaoKChenQJDengFLiuLLYanBZhanFXWangYYXiaoGFShiZLA" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="COVID-19 OutbreakCurr Biol20203013461351.e232197085 9LiuPChenWChenJPViral Metagenomics Revealed Sendai Virus and Coronavirus" exact="Infection" post="of Malayan Pangolins (Manis javanica)Viruses201911 10ChenNZhouMDongXQuJGongFHanYQiuYWangJLiuYWeiYXiaJYuTZhangXZhangLEpidemiological and clinical characteristics"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet202039550751332007143 11LiuKFangYYDengYLiuWWangMFMaJPXiaoWWangYNZhongMHLiCHLiGCLiuHGClinical characteristics of"/>
  <result pre="closely related?Clin Microbiol Infect20202672973432234451 14WuFZhaoSYuBChenYMWangWSongZGHuYTaoZWTianJHPeiYYYuanMLZhangYLDaiFHLiuYWangQMZhengJJXuLHolmesECZhangYZA new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202057926526932015508 15Lu R, Zhao X, Li J,"/>
  <result pre="related?Clin Microbiol Infect20202672973432234451 14WuFZhaoSYuBChenYMWangWSongZGHuYTaoZWTianJHPeiYYYuanMLZhangYLDaiFHLiuYWangQMZhengJJXuLHolmesECZhangYZA new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202057926526932015508 15Lu R, Zhao X, Li J, Niu"/>
  <result pre="17WoelfelRCormanVMGuggemosWSeilmaierMZangeSMuellerMANiemeyerDVollmarPRotheCHoelscherMBleickerTBrueninkSSchneiderJEhmannRZwirglmaierMDrostenCWendtnerCClinical presentation and virological assessment of hospitalized cases of coronavirus" exact="disease" post="2019 in a travel-associated transmission clusterMedRxiv2020 18BaiYYaoLWeiTTianFJinDYChenLWangMPresumed Asymptomatic Carrier"/>
  <result pre="travel-associated transmission clusterMedRxiv2020 18BaiYYaoLWeiTTianFJinDYChenLWangMPresumed Asymptomatic Carrier Transmission of COVID-19JAMA20203231406140732083643 19ZouLRuanFHuangMLiangLHuangHHongZYuJKangMSongYXiaJGuoQSongTHeJYenHLPeirisMWuJSARS-CoV-2" exact="Viral" post="Load in Upper Respiratory Specimens of Infected PatientsN Engl"/>
  <result pre="Asymptomatic Carrier Transmission of COVID-19JAMA20203231406140732083643 19ZouLRuanFHuangMLiangLHuangHHongZYuJKangMSongYXiaJGuoQSongTHeJYenHLPeirisMWuJSARS-CoV-2 Viral Load in Upper" exact="Respiratory" post="Specimens of Infected PatientsN Engl J Med20203821177117932074444 20van DoremalenNBushmakerTMorrisDHHolbrookMGGambleAWilliamsonBNTaminAHarcourtJLThornburgNJGerberSILloyd-SmithJOde"/>
  <result pre="as Compared with SARS-CoV-1N Engl J Med20203821564156732182409 21LiuJLiaoXQianSYuanJWangFLiuYWangZWangFSLiuLZhangZCommunity Transmission of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020Emerg Infect"/>
  <result pre="Compared with SARS-CoV-1N Engl J Med20203821564156732182409 21LiuJLiaoXQianSYuanJWangFLiuYWangZWangFSLiuLZhangZCommunity Transmission of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020Emerg Infect Dis2020261320132332125269"/>
  <result pre="with SARS-CoV-1N Engl J Med20203821564156732182409 21LiuJLiaoXQianSYuanJWangFLiuYWangZWangFSLiuLZhangZCommunity Transmission of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2, Shenzhen, China, 2020Emerg Infect Dis2020261320132332125269 22OngSWXTanYKChiaPYLeeTHNgOTWongMSYMarimuthuKAir,"/>
  <result pre="SARS-CoV-1N Engl J Med20203821564156732182409 21LiuJLiaoXQianSYuanJWangFLiuYWangZWangFSLiuLZhangZCommunity Transmission of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2, Shenzhen, China, 2020Emerg Infect Dis2020261320132332125269 22OngSWXTanYKChiaPYLeeTHNgOTWongMSYMarimuthuKAir, Surface"/>
  <result pre="Dis2020261320132332125269 22OngSWXTanYKChiaPYLeeTHNgOTWongMSYMarimuthuKAir, Surface Environmental, and Personal Protective Equipment Contamination by" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic"/>
  <result pre="22OngSWXTanYKChiaPYLeeTHNgOTWongMSYMarimuthuKAir, Surface Environmental, and Personal Protective Equipment Contamination by Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic PatientJAMA20203231610161232129805"/>
  <result pre="Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic PatientJAMA20203231610161232129805 23LiuTHuJKangMLinLZhongHXiaoJHeGSongTHuangQRongZDengAZengWTanXZengSZhuZLiJWanDLuJDengHHeJMaWTransmission"/>
  <result pre="Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) From a Symptomatic PatientJAMA20203231610161232129805 23LiuTHuJKangMLinLZhongHXiaoJHeGSongTHuangQRongZDengAZengWTanXZengSZhuZLiJWanDLuJDengHHeJMaWTransmission dynamics"/>
  <result pre="Wuhan (2019-nCoV) CoronavirusAm J Respir Crit Care Med20202017831658423 25HamidSMirMYRohelaGKNovel coronavirus" exact="disease" post="(COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics)New Microbes"/>
  <result pre="pandemic (epidemiology, pathogenesis and potential therapeutics)New Microbes New Infect20203510067932322401 26MengLHuaFBianZCoronavirus" exact="Disease" post="2019 (COVID-19): Emerging and Future Challenges for Dental and"/>
  <result pre="InhibitorCell2020181271280.e832142651 31BelserJAAssessment of SARS-CoV-2 replication in the context of other" exact="respiratory" post="virusesLancet Respir Med2020865165232386570 32HuiKPYCheungMCPereraRAPMNgKCBuiCHTHoJCWNgMMTKuokDITShihKCTsaoSWPoonLLMPeirisMNichollsJMChanMCWTropism, replication competence, and innate immune"/>
  <result pre="and innate immune responses of the coronavirus SARS-CoV-2 in human" exact="respiratory" post="tract and conjunctiva: an analysis in ex-vivo and in-vitro"/>
  <result pre="MeulenJKoertenHKMommaasAMUltrastructure and origin of membrane vesicles associated with the severe" exact="acute" post="respiratory syndrome coronavirus replication complexJ Virol2006805927594016731931 34ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKPerlmanSDysregulated Type I"/>
  <result pre="and origin of membrane vesicles associated with the severe acute" exact="respiratory" post="syndrome coronavirus replication complexJ Virol2006805927594016731931 34ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKPerlmanSDysregulated Type I Interferon"/>
  <result pre="origin of membrane vesicles associated with the severe acute respiratory" exact="syndrome" post="coronavirus replication complexJ Virol2006805927594016731931 34ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKPerlmanSDysregulated Type I Interferon and"/>
  <result pre="the severe acute respiratory syndrome coronavirus replication complexJ Virol2006805927594016731931 34ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKPerlmanSDysregulated" exact="Type I" post="Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in"/>
  <result pre="syndrome coronavirus replication complexJ Virol2006805927594016731931 34ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKPerlmanSDysregulated Type I Interferon and" exact="Inflammatory" post="Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected MiceCell Host"/>
  <result pre="Virol2006805927594016731931 34ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKPerlmanSDysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause" exact="Lethal" post="Pneumonia in SARS-CoV-Infected MiceCell Host Microbe20161918119326867177 35ChannappanavarRFehrARZhengJWohlford-LenaneCAbrahanteJEMackMSompallaeRMcCrayPBJrMeyerholzDKPerlmanSIFN-I response timing"/>
  <result pre="34ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKPerlmanSDysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal" exact="Pneumonia" post="in SARS-CoV-Infected MiceCell Host Microbe20161918119326867177 35ChannappanavarRFehrARZhengJWohlford-LenaneCAbrahanteJEMackMSompallaeRMcCrayPBJrMeyerholzDKPerlmanSIFN-I response timing relative"/>
  <result pre="35ChannappanavarRFehrARZhengJWohlford-LenaneCAbrahanteJEMackMSompallaeRMcCrayPBJrMeyerholzDKPerlmanSIFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomesJ Clin Invest20191293625363931355779 36de WitEvan DoremalenNFalzaranoDMunsterVJSARS and MERS: recent"/>
  <result pre="coronavirusN Engl J Med200334950850912890855 39XuZShiLWangYZhangJHuangLZhangCLiuSZhaoPLiuHZhuLTaiYBaiCGaoTSongJXiaPDongJZhaoJWangFSPathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med2020842042232085846 40FanYYHuangZTLiLWuMHYuTKoupRABailerRTWuCYCharacterization of SARS-CoV-specific memory"/>
  <result pre="Engl J Med200334950850912890855 39XuZShiLWangYZhangJHuangLZhangCLiuSZhaoPLiuHZhuLTaiYBaiCGaoTSongJXiaPDongJZhaoJWangFSPathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med2020842042232085846 40FanYYHuangZTLiLWuMHYuTKoupRABailerRTWuCYCharacterization of SARS-CoV-specific memory T"/>
  <result pre="from recovered individuals 4 years after infectionArch Virol20091541093109919526193 41TangFQuanYXinZTWrammertJMaMJLvHWangTBYangHRichardusJHLiuWCaoWCLack of" exact="peripheral" post="memory B cell responses in recovered patients with severe"/>
  <result pre="peripheral memory B cell responses in recovered patients with severe" exact="acute" post="respiratory syndrome: a six-year follow-up studyJ Immunol20111867264726821576510 42ZhaoJLiKWohlford-LenaneCAgnihothramSSFettCZhaoJGaleMJJrBaricRSEnjuanesLGallagherTMcCrayPBJrPerlmanSRapid generation"/>
  <result pre="memory B cell responses in recovered patients with severe acute" exact="respiratory" post="syndrome: a six-year follow-up studyJ Immunol20111867264726821576510 42ZhaoJLiKWohlford-LenaneCAgnihothramSSFettCZhaoJGaleMJJrBaricRSEnjuanesLGallagherTMcCrayPBJrPerlmanSRapid generation of"/>
  <result pre="Immunol20111867264726821576510 42ZhaoJLiKWohlford-LenaneCAgnihothramSSFettCZhaoJGaleMJJrBaricRSEnjuanesLGallagherTMcCrayPBJrPerlmanSRapid generation of a mouse model for Middle East" exact="respiratory" post="syndromeProc Natl Acad Sci USA20141114970497524599590 43WuDYangXOTH17 responses in cytokine"/>
  <result pre="go from bench to bedside?PLoS One20149e8871624551142 45JossetLMenacheryVDGralinskiLEAgnihothramSSovaPCarterVSYountBLGrahamRLBaricRSKatzeMGCell host response to" exact="infection" post="with novel human coronavirus EMC predicts potential antivirals and"/>
  <result pre="2020MMWR Morb Mortal Wkly Rep20206941141532271722 47LauerSAGrantzKHBiQJonesFKZhengQMeredithHRAzmanASReichNGLesslerJThe Incubation Period of Coronavirus" exact="Disease" post="2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and"/>
  <result pre="Wuhan, ChinaLancet202039549750631986264 49ZhouFYuTDuRFanGLiuYLiuZXiangJWangYSongBGuXGuanLWeiYLiHWuXXuJTuSZhangYChenHCaoBClinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="studyLancet20203951054106232171076 50ChenGWuDGuoWCaoYHuangDWangHWangTZhangXChenHYuHZhangXZhangMWuSSongJChenTHanMLiSLuoXZhaoJNingQClinical and immunological features of severe and moderate coronavirus" exact="disease" post="2019J Clin Invest20201302620262932217835 51Giamarellos-BourboulisEJNeteaMGRovinaNAkinosoglouKAntoniadouAAntonakosNDamorakiGGkavogianniTAdamiMEKatsaounouPNtaganouMKyriakopoulouMDimopoulosGKoutsodimitropoulosIVelissarisDKoufargyrisPKarageorgosAKatriniKLekakisVLupseMKotsakiARenierisGTheodoulouDPanouVKoukakiEKoulourisNGogosCKoutsoukouAComplex Immune Dysregulation in COVID-19 Patients"/>
  <result pre="of severe and moderate coronavirus disease 2019J Clin Invest20201302620262932217835 51Giamarellos-BourboulisEJNeteaMGRovinaNAkinosoglouKAntoniadouAAntonakosNDamorakiGGkavogianniTAdamiMEKatsaounouPNtaganouMKyriakopoulouMDimopoulosGKoutsodimitropoulosIVelissarisDKoufargyrisPKarageorgosAKatriniKLekakisVLupseMKotsakiARenierisGTheodoulouDPanouVKoukakiEKoulourisNGogosCKoutsoukouAComplex" exact="Immune Dysregulation" post="in COVID-19 Patients with Severe Respiratory FailureCell Host Microbe2020279921000.e332320677"/>
  <result pre="2019J Clin Invest20201302620262932217835 51Giamarellos-BourboulisEJNeteaMGRovinaNAkinosoglouKAntoniadouAAntonakosNDamorakiGGkavogianniTAdamiMEKatsaounouPNtaganouMKyriakopoulouMDimopoulosGKoutsodimitropoulosIVelissarisDKoufargyrisPKarageorgosAKatriniKLekakisVLupseMKotsakiARenierisGTheodoulouDPanouVKoukakiEKoulourisNGogosCKoutsoukouAComplex Immune Dysregulation in COVID-19 Patients with" exact="Severe" post="Respiratory FailureCell Host Microbe2020279921000.e332320677 52SpinatoGFabbrisCPoleselJCazzadorDBorsettoDHopkinsCBoscolo-RizzoPAlterations in Smell or Taste"/>
  <result pre="Clin Invest20201302620262932217835 51Giamarellos-BourboulisEJNeteaMGRovinaNAkinosoglouKAntoniadouAAntonakosNDamorakiGGkavogianniTAdamiMEKatsaounouPNtaganouMKyriakopoulouMDimopoulosGKoutsodimitropoulosIVelissarisDKoufargyrisPKarageorgosAKatriniKLekakisVLupseMKotsakiARenierisGTheodoulouDPanouVKoukakiEKoulourisNGogosCKoutsoukouAComplex Immune Dysregulation in COVID-19 Patients with Severe" exact="Respiratory" post="FailureCell Host Microbe2020279921000.e332320677 52SpinatoGFabbrisCPoleselJCazzadorDBorsettoDHopkinsCBoscolo-RizzoPAlterations in Smell or Taste in"/>
  <result pre="With SARS-CoV-2 InfectionJAMA20203232089209032320008 53MaoLJinHWangMHuYChenSHeQChangJHongCZhouYWangDMiaoXLiYHuBNeurologic Manifestations of Hospitalized Patients With Coronavirus" exact="Disease" post="2019 in Wuhan, ChinaJAMA Neurol20207768369032275288 54LeviMThachilJIbaTLevyJHCoagulation abnormalities and thrombosis"/>
  <result pre="Coronavirus Disease 2019 in Wuhan, ChinaJAMA Neurol20207768369032275288 54LeviMThachilJIbaTLevyJHCoagulation abnormalities and" exact="thrombosis" post="in patients with COVID-19Lancet Haematol20207e438e44032407672 55WilliamsAEChambersRCThe mercurial nature of"/>
  <result pre="J Physiol Lung Cell Mol Physiol2014306L217L23024318116 56CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJHuman immunopathogenesis of severe" exact="acute" post="respiratory syndrome (SARS)Virus Res2008133131917374415 57ChannappanavarRPerlmanSPathogenic human coronavirus infections: causes"/>
  <result pre="Physiol Lung Cell Mol Physiol2014306L217L23024318116 56CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJHuman immunopathogenesis of severe acute" exact="respiratory" post="syndrome (SARS)Virus Res2008133131917374415 57ChannappanavarRPerlmanSPathogenic human coronavirus infections: causes and"/>
  <result pre="Lung Cell Mol Physiol2014306L217L23024318116 56CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJHuman immunopathogenesis of severe acute respiratory" exact="syndrome" post="(SARS)Virus Res2008133131917374415 57ChannappanavarRPerlmanSPathogenic human coronavirus infections: causes and consequences"/>
  <result pre="cytokine storm and immunopathologySemin Immunopathol20173952953928466096 58MinCKCheonSHaNYSohnKMKimYAigerimAShinHMChoiJYInnKSKimJHMoonJYChoiMSChoNHKimYSComparative and kinetic analysis of" exact="viral" post="shedding and immunological responses in MERS patients representing a"/>
  <result pre="immunological responses in MERS patients representing a broad spectrum of" exact="disease" post="severitySci Rep201662535927146253 59MarceauFBawolakMTFortinJPMorissetteGRoyCBachelardHGeraLCharest-MorinXBifunctional ligands of the bradykinin B2 and"/>
  <result pre="on anticoagulant/thrombolytic therapyJ Thromb Thrombolysis20205027828032372336 62O'DonnellJSSharifKEmeryPBridgewoodCMcGonagleDWhy the immune mechanisms of" exact="pulmonary" post="intravascular coagulopathy in COVID-19 pneumonia are distinct from macrophage"/>
  <result pre="therapyJ Thromb Thrombolysis20205027828032372336 62O'DonnellJSSharifKEmeryPBridgewoodCMcGonagleDWhy the immune mechanisms of pulmonary intravascular" exact="coagulopathy" post="in COVID-19 pneumonia are distinct from macrophage activation syndrome"/>
  <result pre="62O'DonnellJSSharifKEmeryPBridgewoodCMcGonagleDWhy the immune mechanisms of pulmonary intravascular coagulopathy in COVID-19" exact="pneumonia" post="are distinct from macrophage activation syndrome with disseminated Intravascular"/>
  <result pre="intravascular coagulopathy in COVID-19 pneumonia are distinct from macrophage activation" exact="syndrome" post="with disseminated Intravascular coagulationAutoimmun Rev2020 63FoxSEAkmatbekovAHarbertJLLiGBrownQVander HeideRSPulmonary and cardiac"/>
  <result pre="exhaustion levels and reduced functional diversity of T cells in" exact="peripheral" post="blood may predict severe progression in COVID-19 patientsCell Mol"/>
  <result pre="SARS coronavirus infectionVirology200736831732117692881 66YangLTPengHZhuZLLiGHuangZTZhaoZXKoupRABailerRTWuCYLong-lived effector/central memory T-cell responses to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS"/>
  <result pre="coronavirus infectionVirology200736831732117692881 66YangLTPengHZhuZLLiGHuangZTZhaoZXKoupRABailerRTWuCYLong-lived effector/central memory T-cell responses to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patientsClin"/>
  <result pre="infectionVirology200736831732117692881 66YangLTPengHZhuZLLiGHuangZTZhaoZXKoupRABailerRTWuCYLong-lived effector/central memory T-cell responses to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) S antigen in recovered SARS patientsClin Immunol200612017117816781892"/>
  <result pre="S antigen in recovered SARS patientsClin Immunol200612017117816781892 67OkbaNMAMÃ¼llerMALiWWangCGeurtsvanKesselCHCormanVMLamersMMSikkemaRSde BruinEChandlerFDYazdanpanahYLe HingratQDescampsDHouhou-FidouhNReuskenCBEMBoschBJDrostenCKoopmansMPGHaagmansBLSevere" exact="Acute" post="Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease"/>
  <result pre="antigen in recovered SARS patientsClin Immunol200612017117816781892 67OkbaNMAMÃ¼llerMALiWWangCGeurtsvanKesselCHCormanVMLamersMMSikkemaRSde BruinEChandlerFDYazdanpanahYLe HingratQDescampsDHouhou-FidouhNReuskenCBEMBoschBJDrostenCKoopmansMPGHaagmansBLSevere Acute" exact="Respiratory" post="Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease PatientsEmerg"/>
  <result pre="in recovered SARS patientsClin Immunol200612017117816781892 67OkbaNMAMÃ¼llerMALiWWangCGeurtsvanKesselCHCormanVMLamersMMSikkemaRSde BruinEChandlerFDYazdanpanahYLe HingratQDescampsDHouhou-FidouhNReuskenCBEMBoschBJDrostenCKoopmansMPGHaagmansBLSevere Acute Respiratory" exact="Syndrome" post="Coronavirus 2-Specific Antibody Responses in Coronavirus Disease PatientsEmerg Infect"/>
  <result pre="patientsClin Immunol200612017117816781892 67OkbaNMAMÃ¼llerMALiWWangCGeurtsvanKesselCHCormanVMLamersMMSikkemaRSde BruinEChandlerFDYazdanpanahYLe HingratQDescampsDHouhou-FidouhNReuskenCBEMBoschBJDrostenCKoopmansMPGHaagmansBLSevere Acute Respiratory Syndrome Coronavirus 2-Specific" exact="Antibody" post="Responses in Coronavirus Disease PatientsEmerg Infect Dis2020261478148832267220 68WuFWangALiuMWangQChenJXiaSLingYZhangYXunJLuLJiangSLuHWenYHuangJNeutralizing antibody"/>
  <result pre="HingratQDescampsDHouhou-FidouhNReuskenCBEMBoschBJDrostenCKoopmansMPGHaagmansBLSevere Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus" exact="Disease" post="PatientsEmerg Infect Dis2020261478148832267220 68WuFWangALiuMWangQChenJXiaSLingYZhangYXunJLuLJiangSLuHWenYHuangJNeutralizing antibody responses to SARS-CoV-2 in"/>
  <result pre="patientsNat Commun202011280632483236 70PayneDCIblanIRhaBAlqasrawiSHaddadinAAl NsourMAlsanouriTAliSSHarcourtJMiaoCTaminAGerberSIHaynesLMAl AbdallatMMPersistence of Antibodies against Middle East" exact="Respiratory" post="Syndrome CoronavirusEmerg Infect Dis2016221824182627332149 71GrahamRLDonaldsonEFBaricRSA decade after SARS: strategies"/>
  <result pre="Commun202011280632483236 70PayneDCIblanIRhaBAlqasrawiSHaddadinAAl NsourMAlsanouriTAliSSHarcourtJMiaoCTaminAGerberSIHaynesLMAl AbdallatMMPersistence of Antibodies against Middle East Respiratory" exact="Syndrome" post="CoronavirusEmerg Infect Dis2016221824182627332149 71GrahamRLDonaldsonEFBaricRSA decade after SARS: strategies for"/>
  <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
  <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
  <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ"/>
  <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ Infect Dis2015211809025030060"/>
  <result pre="Modified Tool for Initial Detection and Management of Middle East" exact="Respiratory" post="Syndrome Patients in the Emergency DepartmentWest J Emerg Med20151661962426587081"/>
  <result pre="Tool for Initial Detection and Management of Middle East Respiratory" exact="Syndrome" post="Patients in the Emergency DepartmentWest J Emerg Med20151661962426587081 75TianXLiCHuangAXiaSLuSShiZLuLJiangSYangZWuYYingTPotent"/>
  <result pre="Invest20201301545154832167489 78VelikovaTVMitevaLStanilovNSpassovaZStanilovaSAInterleukin-6 compared to the other Th17/Treg related cytokines in" exact="inflammatory bowel disease" post="and colorectal cancerWorld J Gastroenterol2020261912192532390702"/>
  <result pre="78VelikovaTVMitevaLStanilovNSpassovaZStanilovaSAInterleukin-6 compared to the other Th17/Treg related cytokines in inflammatory" exact="bowel" post="disease and colorectal cancerWorld J Gastroenterol2020261912192532390702"/>
  <result pre="compared to the other Th17/Treg related cytokines in inflammatory bowel" exact="disease" post="and colorectal cancerWorld J Gastroenterol2020261912192532390702"/>
 </snippets>
</snippetsTree>
